KRINGLE PHARMA, INC.
14Patents
10Active
14Granted
40Portfolio score
Filing activity: Mar 24, 2004 → Dec 28, 2018 · 6 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7563768B2 | Asthma preparation | Emerging Cross-Sectional Technologies | 12 | Expired |
| US8575099B2 | Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof | Chemistry; Metallurgy | 2 | Active |
| US7696170B2 | Fibrosis inhibitor for implanted organ | Human Necessities | 2 | Expired |
| US10213485B2 | HGF preparation suitable for treatment of neurological disorders | Human Necessities | 2 | Active |
| US8927493B2 | Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue | Human Necessities | 2 | Active |
| US8518880B2 | Therapeutic agent for spinal cord injuries | Human Necessities | 1 | Active |
| US7838494B2 | Differentiation- or regeneration-inducing agent for alveoli | Human Necessities | 1 | Expired |
| US8461112B2 | HGF preparation | Human Necessities | 0 | Active |
| US8003607B2 | HGF precursor protein variant and active protein thereof | Human Necessities | 0 | Active |
| US7807177B2 | Segment of glycosylation-deficient HGFalpha-chain | Chemistry; Metallurgy | 0 | Expired |
| US8278270B2 | HGF precursor protein variant and active protein thereof | Human Necessities | 0 | Active |
| US8076289B2 | Fibrosis inhibitor for implanted organ | Human Necessities | 0 | Active |
| US8383588B2 | Fibrosis inhibitor for implanted organ | Human Necessities | 0 | Active |
| US10702582B2 | HGF preparation suitable for treatment of neurological disorders | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.